GAITHERSBURG, Md., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately $171 million by the U.S. Department of Defense (DoD) to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. The RSDL Kit is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin.
“Emergent’s continued supply of RSDL reinforces our longstanding commitment to partner with governments around the world to provide life-saving products that protect against chemical and biological health threats,” said Sean Kirk, senior vice president, manufacturing operations and interim head, devices business unit at Emergent BioSolutions. “We are pleased with this renewed DoD contract, which follows a recent successful launch of RSDL in the commercial market. Supporting preparedness efforts of both civilians and military forces is an important part of Emergent’s mission – to protect life.”
RSDL has been cleared by the U.S. Food and Drug Administration (FDA) and licensed by Health Canada, the Israeli Ministry of Health, and the Australian Therapeutic Goods Administration. RSDL is a Class IIa CE marked medical device in Europe. It has been procured for military and first responder use for over a decade and has been deployed in over 30 countries. RSDL is available for purchase by civilians in the U.S. on Amazon.com.
The RSDL Kit is an FDA-cleared decontaminant that removes or neutralizes chemical warfare agents and T-2 toxin from the skin. It consists of a sponge impregnated with a lotion in an impermeable packet. Decontamination occurs by physical removal of the chemical warfare agent from the skin or by chemical neutralization. The RSDL Kit is lightweight, portable, and has been deployed by the U.S. military for over 10 years. RSDL is for external use only, to be used only if chemical warfare agent exposure is suspected. Use RSDL only as directed. It is not intended for prophylactic use or decontamination of the whole body.
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the availability of funding and the exercise of options under the DoD contract; the ability to obtain and maintain regulatory approvals for the product; and our commercialization, marketing and manufacturing capabilities. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications
Emergent BioSolutions Inc.